Yazarlar : Tayman C, Uckan D, Kilic E, Tulga Ulus A, Tonbul A, Murat Hirfanoglu I, Helvacioglu F, Haltas H, Koseoglu B, Tatli MM.
Yayın : Pediatr Res.
Yayın Yılı : 2011
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21772224
Konu : Rejeneratif Tıp
Literatür İçeriği :
Abstract
We evaluated the potential therapeutic use of exogenous human bone marrow-derived mesenchymal stem cells (hBM-MSCs) in an experimental rat model of necrotizing enterocolitis (NEC). Thirty-six newborn Sprague-Dawley rats were randomly divided into three groups: NEC, NEC + hBM-MSC, and a control (control and control + hBM-MSC). NEC was induced by enteral formula feeding, exposure to hypoxia-hyperoxia, and cold stress. After NEC was induced, iron-labeled hBM-MSCs were administered by intraperitoneal injection. All pups were killed on the fourth day following injection, and the terminal ileum was excised for a histopathological and immunohistochemical evaluation. The pups in the NEC + hBM-MSC group showed significant weight gains and improvements in their clinical sickness scores (P < 0.01). Bowel damage severity observed in the histopathological evaluation was significantly lower in the NEC + hBM-MSC group than that in the NEC group (P = 0.012). The number of MSCs homing to the bowel was significantly higher in the NEC + hBM-MSC group than that in the control + hBM-MSC group. In conclusion, this is the first study that has evaluated the effectiveness of hBM-MSCs in a neonatal rat NEC model. MSCs reduced histopathological damage significantly.
| Sunumlar | Videolar | Olgu Tartışması |
